Langer and fellow MIT professor Michael Cima developed an early version of an implantable drug-delivery chip in the late 1990s. They co-founded a company called MicroCHIPS Inc., which administered the study being published today in Science Translational Medicine. The team decided to work with osteoporosis patients because the disease, and the drug used to treat it, presented a series of special opportunities, Langer said. A widely used drug called teriparatide can reverse bone loss in people with severe osteoporosis, but it requires a daily injection to work properly. This means up to 75 percent of patients give up on the therapy, Langer said. It's also a very potent drug that requires microgram doses, making it an ideal candidate for a long-term dispensary implant.